Secondary Pulmonary Alveolar Proteinosis Development during the Treatment for Anti-aminoacyl-tRNA Synthetase Antibody-positive Interstitial Lung Disease

Intern Med. 2024 Nov 1;63(21):2971-2976. doi: 10.2169/internalmedicine.3327-23. Epub 2024 Mar 25.

Abstract

A 70-year-old woman with anti-aminoacyl-tRNA synthetase (ARS) antibody-positive interstitial lung disease (ARS-ILD) received daily medications and regular cyclophosphamide cycles for recurring exacerbations. Approximately four years after immunosuppression initiation, the patient was admitted for progressive dyspnea on exertion. Chest computed tomography (CT) findings were suggestive of acute exacerbation. Despite intensified immunosuppressive treatment, the radiographic findings worsened, and serum Krebs von den Lungen-6 (KL-6) levels increased. A bronchoalveolar lavage fluid (BALF) examination revealed amorphous globules and alveolar macrophages with eosinophilic granules. Owing to negative anti-granulocyte-macrophage colony-stimulating factor antibody tests, a diagnosis of secondary pulmonary alveolar proteinosis (PAP) was established.

Keywords: anti-aminoacyl-tRNA synthetase antibody-positive interstitial lung disease; immunosuppressants; secondary pulmonary alveolar proteinosis; steroid.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Amino Acyl-tRNA Synthetases* / immunology
  • Autoantibodies* / blood
  • Bronchoalveolar Lavage Fluid / cytology
  • Bronchoalveolar Lavage Fluid / immunology
  • Cyclophosphamide / therapeutic use
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lung Diseases, Interstitial* / diagnosis
  • Lung Diseases, Interstitial* / diagnostic imaging
  • Lung Diseases, Interstitial* / drug therapy
  • Lung Diseases, Interstitial* / etiology
  • Lung Diseases, Interstitial* / immunology
  • Pulmonary Alveolar Proteinosis* / diagnosis
  • Pulmonary Alveolar Proteinosis* / immunology
  • Tomography, X-Ray Computed

Substances

  • Amino Acyl-tRNA Synthetases
  • Autoantibodies
  • Immunosuppressive Agents
  • Cyclophosphamide